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Abstract
Transcriptional activation and repression are a key step in the regulation of all cellular activities. The
development of comprehensive analysis methods such as DNA microarray has advanced our understand-
ing of the correlation between the regulation of transcription and that of cellular mechanisms. However,
DNA microarray analysis based on steady-state mRNA (total mRNA) does not always correspond to tran-
scriptional activation or repression. To comprehend these transcriptional regulations, the detection of
nascent RNAs is more informative. Although the nuclear run-on assay can detect nascent RNAs, it has
not been fully applied to DNA microarray analysis. In this study, we have developed a highly efﬁcient
method for isolating bromouridine-labeled nascent RNAs that can be successfully applied to DNA micro-
array analysis. This method can linearly amplify small amounts of mRNAs with little bias. Furthermore, we
have applied this method to DNA microarray analysis from mouse G2-arrested cells and have identiﬁed
several genes that exhibit novel expression proﬁles. This method will provide important information in
the ﬁeld of transcriptome analysis of various cellular processes.
1. Introduction
DNAmicroarrayisanimportanttoolforunderstand-
ing regulatory networks. In fact, this technique was
used to analyze changes in the amounts of mRNA in
cellularphenomenasuchascelldifferentiation,cellular
senescence, andcellcycleprogressioninacomprehen-
sive manner. Moreover, we have successfully improved
the sensitivity and reproducibility of DNA microarray
analysis.
1 Although many of the expression proﬁle
data obtained through DNA microarray analysis
are available at various websites, such data are
based on steady-state mRNA levels. It is obvious
that both mRNA synthesis and degradation inﬂuence
steady-state mRNA levels, but usually only the total
mRNA is quantiﬁed. If we can quantify nascent mRNA
in a real-time manner, it will become possible to esti-
mate mRNA synthesis and degradation rates by com-
paring the nascent amount with the total amount of
RNA measured by an ordinary DNA microarray
system. One method of detecting nascent mRNA is
the nuclear run-onassay.
2Recently, thetranscriptional
proﬁling of radio-labeled RNAs using the nylon-
membrane DNA microarray was reported.
3–5 The
current standard platforms are GeneChip by
Affymetrix, the Stanford-type DNA microarray, and
the oligo-DNA microarray. In general, it is very difﬁcult
to compare data from such standard DNA microarray
systems with data obtained by the nylon membrane
DNA microarray. To comprehensively analyze nascent
RNAsusingthesecurrentstandardplatforms,improved
methods for the isolation and labeling of nascent
mRNAs were reported. Cleary et al. used uracil phos-
phoribosyltransferase gene-transformed human cells
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grown in 2,4-dithiouracil were labeled with thio-
substratedUTP,puriﬁed,andanalyzedbyDNAmicroar-
ray.
6 However, it is necessary to introduce this gene to
thecelltobeanalyzedpriortoDNAmicroarrayanalysis.
Bromouridine, which substitutes 50 of uridine to
bromine, is inexpensive and becomes incorporated
into cells with very high efﬁciency. Additional steps,
such as electroporation or lipofection, are not necess-
ary for labeling mRNA with this compound. After its
incorporation into cells, bromouridine is converted
to Br-UTP. During transcription, converted Br-UTP is
recognized as the same substrate as UTP and is incor-
porated into nascent RNAs.
7 This labeling method
was applied in the immunocytochemical analysis
by using anti-bromodeoxyuridine (BrdU) antibody
in several studies.
8–11 That antibody was used also
to immunoprecipitate this BrU-labeled nascent
RNA.
12,13 The same reports analyzed transcriptional
changes of some genes in small amounts (on the
order of the picogram) of nascent RNAs.
12,13
For a comprehensive analysis using DNA microarray,
we have optimized the conditions for immunoprecipi-
tation using BrdU antibody. We have improved the
speciﬁcity of nascent mRNA isolation by orders of
magnitude using adequate blocking agents in immu-
noprecipitation. As the amount of nascent RNA
obtained was very small even under the optimized
puriﬁcation conditions, we sought to develop a
method for amplifying small amounts of mRNA
with little bias and have succeeded in this goal.
Finally, we have performed transcriptional analysis of
nascent RNAs using G2 phase-synchronized mouse
mammary carcinoma FM3A cells, and we have
obtained several interesting insights into cell cycle
regulation of the G2 phase.
These results demonstrate that DNA microarray
analysis with nascent RNAs obtained by our new
method will provide valuable insights into the
functions of genes in various types of cells.
2. Materials and Methods
2.1. Preparation of BrU-labeled eGFP cRNA and
non-labeled luciferase cRNA
eGFP cRNA and luciferase cRNA were prepared by T7
invitrotranscription.DNAtemplatesforeachcRNA syn-
thesis were constructed by PCR ampliﬁcation from
plasmid DNA containing eGFP or luciferase genes.
These templates contain both T7 promoter sequence
and polyA sequence. The DNA template of eGFP was
ampliﬁed from pEGFP-c1 by PCR. The DNA template
of luciferase was ampliﬁed from pTRE (Clontech,
Mountain View, CA, USA) by PCR. Sequences of primers
were described in ‘Supplementary data’. The PCR
products were puriﬁed from agarose gel by using
Wizard SV gel and PCR puriﬁcation kit (Promega,
Madison, WI, USA).
cRNAs were transcribed with Br-UTPs (Sigma-
Aldrich, St Louis, MO, USA) and NTPs using the
MAXIscript
w T7 kit. cRNAs were puriﬁed according
to the RNA-cleanup protocol of the RNeasy Mini kit
(Qiagen, Hilden, Germany).
2.2. Preparation of Mouse anti-BrdU IgG binding
dynabeads
Two micrograms of mouse anti-bromodeoxyuridine
antibody (Roche Diagnostics, Indianapolis, IN, USA)
were incubated with 25 ml Dynabeads
w Goat anti-
mouse IgG (Invitrogen, Carlsbad, CA, USA) in 2.0 ml
collection tubes containing 100 ml DEPC-treated
phosphate-buffered saline (PBS)/0.1% bovine serum
albumin (BSA) solution. The tubes were rotated at
room temperature for an hour. After the dynabeads
were collected by a magnet rack, the dynabeads
were washed three times with 1 ml DEPC-treated
PBS/0.1% BSA, and 100 ml DEPC-treated PBS /0.1%
BSA was added.
2.3. Immunoprecipitation of BrU-labeled RNA by
antibody beads
Following steps were conducted in the dark. Two
hundred nanograms of BrU-labeled eGFP cRNA and
200ng of non-labeled luciferase cRNA were
denatured at 808C for 10 min. As the blocking
agent, 20 mg FM3A total RNA or 200 mg Escherichia
coli 16S and 23S ribosomal RNA (rRNA) or uridine
(ﬁnal concentration of 0.3 M) was added. The
denatured RNAs were added to the beads containing
225U/ml RNasin
w Plus RNase inhibitor (Promega).
PBS(-)/0.1% BSA was added to this solution to a
volume of 250 ml. The beads were rotated for 1 h at
room temperature. After the beads were washed
with 0.8 ml DEPC-treated PBS/0.1% BSA containing
45 U/ml RNasin
w Plus RNase inhibitor (Promega),
they were also washed with 0.8ml DEPC-treated PBS
three times. After the addition of 10 mlo fR N a s e -
free water, RNAs which bound to beads were eluted
by denaturation at 808C for 10 min, and then were
kept cold on ice for 2 min.
2.4. Reverse transcription of cRNA and Real-time
RT–PCR
2.4.1. Reverse transcription of cRNA Five micro-
liters of the isolated RNAs were mixed with 1mlo f
50 mM oligo(dT)20 primer and denatured at 658C
for 5 min. First-strand cDNAs were synthesized from
the isolated RNAs using the SuperScript
w III First-
Strand Synthesis System for RT–PCR (Invitrogen).
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reacted for 20 min at 378C.
2.4.2. Real-time quantitative RT–PCR Real-time
quantitative PCR was performed in an ABI prism
7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using SYBR
w Premix
Ex Taq
TM (Perfect Real Time) (Takara Bio, Otsu,
Japan). Sequences of each primer were described in
‘Supplementary data’. The PCR cycling program was
set as follows: 958C for 15 s followed by 40 cycles
of 958C for 5 s and 608C for 34 s. One of cDNAs
diluted 100 times was used in a 50 ml reaction. A
standard graph for eGFP cDNA and luciferase cDNA
was simultaneously generated using 10
4,1 0
5,1 0
6,
10
7, and 10
8 copies of the pEGFP plasmid and the
pTRE plasmid. Each cDNA was analyzed in triplicate.
Three experiments were conducted, and the averages
of the cDNA copy numbers as well as standard
deviation were calculated.
2.5. Cell culture of FM3A cells and labeling nascent
RNA with BrU
Mouse FM3A cells and tsFT210 cells, Cdc2 temp-
erature-sensitive mutant strain of FM3A cells,
14,15
were cultured in RPMI 1640 medium (Invitrogen)
with 10% dialyzed bovine serum, 2 mM L-glutamine,
0.1 mM MEM non-essential amino acid (Invitrogen),
and 50 U/ml penicillin–50 mg/ml streptomycin
(Invitrogen) at 328Ci n5 %C O 2.
After bromouridine was added to the medium to a
ﬁnal concentration of 100 mM, FM3A cells were cul-
tured for an hour in the dark. FM3A cells were col-
lected in 50 ml centrifuge tubes and washed twice
with cold PBS, and total RNA was isolated by using
an RNeasy midi kit (Qiagen). DNase I digestion was
conducted during isolation of RNA.
2.6. Immunoprecipitation of nascent RNA from mouse
FM3A cells
Twenty micrograms of total RNA from bromouri-
dine-treated FM3A were immunoprecipitated with
200 mgo fE. coli 16S and 23S rRNAs. The method of
immunoprecipitation was described above. The
amount of the eluted RNA was measured using
the Quant-iT
TM RiboGreen
w RNA quantitation kit
(Invitrogen). Five hundred nanometers of ﬂuor-
escence of the RiboGreen reagent bound to RNA
were measured using the ﬂuorescence microplate
reader ARVO (Perkin Elmer, Boston, MA, USA).
2.7. Spike-in experiment
Both BrU-labeled eGFP cRNA and non-labeled luci-
ferase cRNA were added to 20 mg of total RNA from
bromouridine-treated FM3A cells. We conducted
three different kinds of experiments. Each experiment
was performed with a different amount of cRNAs (2
ng, 200 pg, or 20 pg). These RNAs were immunopre-
cipitated with 200 mg E. coli 16S and 23S rRNAs
as blocking agents.
2.8. Validation with RT–PCR of the DNA microarray
data using each ampliﬁcation method
Methods of experiences were described in
‘Supplementary data’.
2.9. Preparation of DNA Microarray
Oligonucleotide probe sets of Mus musculus AROS
Version 3.0 (Operon Biotechnologies, Huntsville, AL,
USA) were dissolved at 10 mMi n3   SSPE solution
(Invitrogen), and spotted on g-amino propyl silane-
coated UltraGAPS Coated Slides (Corning, New York,
NY, USA) and UV cross-linked as described previously.
1
2.10. cDNA synthesis and ampliﬁcation
The ampliﬁcation of RNA was performed using the
Super SMARTTM PCR cDNA Synthesis Kit (Clontech) as
follows. We have modiﬁed the manufacture’s protocol
and optimized it for our DNA microarray system. Total
RNA (20 ng) was mixed with 7mlo f1 2mM3 0 SMART
CDS Primer II A and 7mlo f1 2 mM SMART II A
Oligonucleotide, incubated at 658C for 2 min, and
cooled to room temperature. To this mixture was
added 20 mlo f5   First-Strand Buffer, 2ml of 100
mM DTT, 10 mlo f1 0m Mo f5 0   dNTP, and 5mlo f
PowerScriptTM Reverse Transcriptase, and the reaction
was incubated at 428C for 90 min. After the reaction,
1 ml of 0.5 M EDTA was added. First-strand cDNA
was puriﬁed with the NucleoSpin Extraction Kit
(Clontech). For the ampliﬁcation by long-distance
PCR using the Advantage
w 2 PCR Kit (Clontech), ﬁrst--
strand cDNAwasmixed with 10 mlo f1 0  Advantage
w
2PCRBuffer,2mlof10mM50  dNTP,2mlof12mMof
50PCR Primer II A, and 2 mlo f5 0   Advantage
w 2
Polymerase Mix. The PCR conditions consisted of a
958C for 1 min, followed by appropriate number of
cycles of ampliﬁcation at 958C for 15 s, 658C for 30 s,
and 688C for 6 min. The appropriate number of
cycling on which the PCR product will remain in the
exponential phase of ampliﬁcation was determined
by the cDNA ampliﬁcation results of the range of PCR
cycles obtained in pre-experiments. The PCR product
was puriﬁed with Wizard SV Gel and PCR Clean-Up
System (Promega). For aminoallyl labeling, 1mg cDNA
was mixed with 15 ml of Random Primers Buffer
Mixture (Invitrogen), incubated at 958C for 5 min,
and cooled on ice. Then, 5ml of an aminoallyl–dNTP
mixture which contained 5 mM aminoallyl–dUTP
(Sigma), 5 mM dATP (GE healthcare, Uppsala,
Sweden), 5 mM dGTP (GE healthcare), and 5 mM
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Fragment (Invitrogen) was added and incubated at
378C for 120 min. After the reaction, 5ml of Stop
Buffer (Invitrogen) was added. Aminoallyl-labeled
cDNAwaspuriﬁedwithethanolprecipitationfollowing
theﬁrstpuriﬁcationwithWizard SVGelandPCRClean-
Up System. For the coupling reaction, aminoallyl-
labeled cDNA was dissolved with 5ml of 0.1 M
NaHCO3 and mixed with 5ml of Cy3 Mono-reactive
Dye (GE healthcare) or Cy5 Mono-reactive Dye (GE
healthcare) in 50 ml Atlas Glass Approved DMSO (BD
Bioscience), and incubated for 60 min at room temp-
erature. After coupling, 15 ml of 4 M hydroxylamine–
HCl (Sigma-Aldrich) was added and incubated at
room temperature for 15 min. Cy-Dye labeled cDNA
was puriﬁed with the MinElute Reaction Cleanup Kit
(Qiagen).
2.11. Hybridization
These procedures were based on TF oligo micro-
array hybridization as described previously.
1 Some of
the conditions and compositions of solutions were
changed: the hybridization solution consisted of a
mixture of Cy3- and Cy5-labeled cDNAs, 40% forma-
mide, 5  SSC, 0.4% SDS, and 1.9 mg/ml acetylated BSA
(Invitrogen). Hybridization was performed with a
hybridization chamber (Agilent Technologies, Palo
Alto, CA, USA) and a hybridization gasket slide
(Agilent Technologies). The temperature in both the
pre-hybridization and hybridization steps was 458C.
Hybridization images were scanned using an Agilent
DNA microarray scanner (Agilent Technologies).
We hybridized four slides as self–self hybridization:
Cy3-labeled cDNAs of nascent RNA from FM3A cells
and Cy5-labeled cDNA of nascent RNA from FM3A
cells.
In experiments using G2 phase-arrested cells, we
hybridized four slides: Cy3-labeled cDNAs of
asynchronous cells and Cy5-labeled cDNAs of G2
phase-arrested cells were hybridized in two slides,
and dye-swapped cDNAs were hybridized in the
other two.
2.12. DNA microarray analyses
Fluorescence intensities in spots were quantiﬁed
using Feature Extraction software version GX
(Agilent Technologies). Spots ﬂagged as non-uniform
outliners of either a feature (spot) or background
were removed. In each array, genes whose expression
levels were lower than those of the negative control
spots under both conditions were removed. The
ratios of signal intensities between the two cell types
were calculated through Lowess normalization using
GeneSpring GX (Agilent Technologies). We calculated
the average and the standard deviation of the base
2 logarithm of the expression ratios of four spots
and removed the expression ratios of genes whose
standard deviation was .1. The expression ratios of
genes whose average signal intensity was ,50 were
also removed.
2.13. Analyses of nascent RNA proﬁles in G2-arrested
cells and asynchronous cells
tsFT210 cells were arrested in the G2 phase by incu-
bation for 17 h at a non-permissive temperature
(398C). Bromouridine was added to the medium to
a concentration of 100 mM at 16 h after the shift at
398C. RNA was isolated using the RNeasy mini kit
(Qiagen). DNase I digestion was conducted during iso-
lation of RNA. The DNA microarray analyses are
described above.
2.14. Cell cycle analysis
Cells were harvested, washed with PBS, and ﬁxed in
70% ethanol at 2208C for at least 4 h. Fixed cells were
washed twice with PBS and mixed with PBS containing
0.3% Triton X-100 (w/v) (Sigma-Aldrich). Cells were
added with PBS (2) containing 50 mg/ml propidium
iodide (Sigma-Aldrich) and 0.1 mg/ml RNase A
(Sigma-Aldrich), and incubated for 20 min at 378C
in the dark before being ﬁltered through a 41 mm
nylon mesh. We analyzed the DNA contents by
measuring the intensity of the ﬂuorescence produced
by propidium iodide using the FACSCalibur instru-
ment (Beckon Dickinson, Mountain View, CA, USA)
using instructions supplied by the manufacturer.
3. Results and Discussion
3.1. Experimental scheme of DNA microarray analysis
for the nascent RNA
The new method for performing comprehensive
analyses of nascent RNA is illustrated in Fig. 1. In the
ﬁrst step, bromouridine was added to the culture
medium. This compound was incorporated into
cells, which converted it to Br-UTP. As BrUTP is recog-
nized as the same substrate as UTP, nascent mRNA is
labeled by BrU
7 (Fig. 1). Total RNAs isolated from
the BrU-treated cells were immunoprecipitated with
anti-BrdU antibody beads.
12,13 The RNAs bound to
the beads were eluted by heat denaturation after
washing, and the eluted mRNAs were reverse-
transcribed using oligo-dT primer. The cDNAs were
linearly ampliﬁed using the template-switching (TS)
PCR method. The ampliﬁed cDNAs labeled with
Cy3/Cy5 were used for DNA microarray analysis
(Fig. 1). Among these steps, the method for immuno-
precipitating the BrU-labeled nascent RNAs was based
on a method described previously
12,13 and optimized
for DNA microarray analysis in the following manner.
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mouse pre-implantation embryos was obtained and
subjected to the same analysis as used in a previous
study.
13 The RNA amount should be .20 ng in total
RNA. This is  1000 times more than that in the pre-
vious study.
Therefore, it was necessary to develop a method for
immunoprecipitating a large amount of BrU-labeled
RNA with high speciﬁcity.
3.2. Determination of optimum conditions for
enriching nascent RNAs using cRNAs
synthesized in vitro
As the amount of BrU-labeled nascent RNAs is
much smaller than that of non-labeled RNAs in the
RNA fractions extracted from living cells, it was necess-
ary to develop a method for obtaining BrU-labeled
RNAs with high recovery as well as on a certain
scale. In the ﬁrst trial, a mixture of BrU-labeled eGFP
cRNAs and non-labeled luciferase cRNAs prepared
by T7 in vitro transcription was immunoprecipitated
in the same tube. cRNAs eluted from the afﬁnity
beads were reverse-transcribed with oligo-dT primer,
and the copy number of each cDNA was quantiﬁed
by real-time quantitative PCR (Fig. 2A). We deﬁned
the ratio of the eGFP cDNA copy number to the luci-
ferase cDNA copy number as the index of immuno-
precipitation speciﬁcity. This index well reﬂects the
enrichment efﬁciency of nascent mRNAs. We also
examined the effects of adding blocking agents such
as uridine, total RNA from FM3A cells, and E. coli
16S and 23S rRNAs. Although interferon-t RNA was
shown to work well as a blocker in a previous
report,
13 we chose uridine, E. coli rRNA, and mouse
total RNA as candidates for a blocking agent
because we thought they would be more suitable
for large-scale isolation of nascent RNAs. We evalu-
ated the effects of these blocking agents with increas-
ing amounts of cRNA. Under our conditions, the
addition of uridine did not change the ratio. In con-
trast, the ratios observed in the experiments with
E. coli rRNA or FM3A total RNA were approximately
double those obtained in an experiment carried out
without RNAs as the blocking agent (Fig. 2B). These
data suggest that any kind of RNA can increase the
speciﬁcity of the immunoafﬁnity puriﬁcation of
nascent RNAs. We thus chose E. coli 16S and 23S
rRNAs as suitable blocking agents. These bacterial
rRNAs are inexpensive and do not exist in mammalian
cells. In addition, E. coli 16S and 23S rRNAs should
not be reverse-transcribed when mRNA is reverse-
transcribed by using oligo-dT primer.
3.3. Conditions for labeling nascent RNAs with BrU
Next, we treated living cells with bromouridine and
immunoprecipitated BrU-labeled nascent RNAs from
BrU-treated cells. We ﬁrst tested and determined the
appropriate concentration (100mM) of bromouridine,
i.e. that which did not affect proliferation and cell cycle
progression in mouse FM3A cells (data not shown).
Using DNA microarray analysis, we also conﬁrmed
that the gene expression proﬁle of FM3A cells after
treatment with 100mM bromouridine for 4h was
extensively the same as that of untreated cells (data
not shown). Approximately 20mg total RNA was
isolated from 2   10
6 FM3A cells that had been
treated with 100mMb r o m o u r i d i n ef o r1h ;t h i st o t a l
RNA was then subjected to immunoafﬁnity puriﬁ-
cation. We used E. coli 16S and 23S rRNAs as blocking
agents. The amount of eluted RNAs in the sample of
BrU-treated cells was  30ng, so we had successfully
obtained a sufﬁcient amount of BrU-labeled RNA
for DNA microarray analyses. We then evaluated the
speciﬁcity of immunoafﬁnity puriﬁcation.
Figure 1. Overview of the isolation of nascent RNAs for microarray
analysis.
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spike-in control
To more preciselyestimate the efﬁciency with which
nascent RNAs were puriﬁed, small amounts of T7
in vitro transcribed BrU-labeled eGFP cRNA and non-
labeled luciferase cRNA were added to the RNAs
obtained from BrU-treated FM3A cell samples as the
‘spike-in’ control. We immunoprecipitated these RNA
mixtures and compared the cDNA copy numbers of
eluted eGFP cDNA and luciferase cDNA. To determine
whether or not the amount of the eluted BrU-labeled
eGFP cRNA was proportional to that of the input
eGFP cRNA, increasing amounts (20pg, 200 pg, and
2 ng) of eGFP cRNA and luciferase cRNA were added
to 20 mg of BrU-labeled total RNA obtained from
FM3A cells (Fig. 3A). The ratio of eluted eGFP cDNA
to eluted luciferase cDNA exceeded 83 under the con-
ditions shown in Fig. 3B. In addition, the copy number
of eluted BrU-labeled eGFP cRNA was proportional to
that of the input eGFP cRNA. These results indicated
that we were able to immunoafﬁnity-purify BrU-
labeled RNA with high speciﬁcity and that the eluted
RNA reﬂects the nascent RNA before immunoprecipi-
tation. Taken together, these ﬁndings indicate that
we have successfully optimized the conditions for
immunoafﬁnity-puriﬁcation with high speciﬁcity. It
was already demonstrated that the enrichment
process using anti-BrdU immunoafﬁnity beads does
not have any bias.
13 As it is important to conﬁrm that
the cDNA ampliﬁcation process does not have any sig-
niﬁcant bias, we performed the following experiments.
3.5. DNA microarray analyses of nascent RNAs
To carry out DNA microarray analysis, nascent RNAs
of BrU-treated cells have to be ampliﬁed without bias.
We previously developed a method for effectively
amplifying small amounts of RNA using the TS-PCR
reaction
16 (Fig. 4A). To examine whether or not this
ampliﬁcation method has any ampliﬁcation bias, we
compared the data obtained by DNA microarray
analysis with those obtained by quantitative real-
time PCR using RNA samples prepared from ES
cells.
1 We considered that the efﬁciency of ampliﬁca-
tion would vary according to the differences in cellu-
lar RNA abundance. Genes with abundant RNA would
be ampliﬁed without bias, but genes with low
amounts of RNA might fail to be ampliﬁed accurately.
As the expression levels of transcription-factor genes
are generally much lower than those of genes in
other categories, we focused on expression changes
of the transcription factor genes. We used the TF
oligo microarray, which can accurately determine
expression changes of transcription factor genes.
1 As
shown in Fig. 4B, the expression changes in TS-PCR
Figure 2. Binding speciﬁcity of BrU-labeled cRNA by in vitro
transcription. (A) eGFP and luciferase gene were transcribed
in vitro by T7 RNA polymerase. Br-UTP was used as the
substrate instead of UTP during the transcription of eGFP.
(B) Mixture of 200ng of BrU-labeled eGFP and non-labeled
luciferase cRNA was immunoprecipitated with addition to
blocking agents. The eluted cRNAs were converted into cDNA,
and then the cDNA copy number was measured using real-
time quantitative PCR. The blocking agents used are as
follows: (i) no addition, (ii) uridine, (iii) E. coli 16S and 23S
RNAs, and (iv) total RNA from mouse FM3A cells. ‘Ratio
(eGFP/Luci.)’ represents the ratio of the eGFP cDNA copy
number to the luciferase copy number. Error bars represent
standard errors of the means (n ¼ 3).
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ampliﬁcation bias, except for Prdx1, Rara. Especially,
the fold changes of Dcx, Meis1, and Ttyh1 obtained
by TS PCR were not only quite similar to the data
obtained without ampliﬁcation, but were also
similar to the data from quantitative real-time PCR,
whereas ampliﬁcation by in vitro transcription with
T7 promoter exhibited some discrepancies. Thus,
ampliﬁcation by TS PCR has very little bias (Fig. 4B).
However, there was a possibility that ampliﬁcation
efﬁciency and the reverse-transcription efﬁciency
of BrU-labeled mRNA were different from that of
non-labeled mRNA, so we compared the agarose-gel
electrophoresis pattern of ampliﬁed cDNA from BrU-
labeled mRNA (nascent mRNA) with that from non-
labeled mRNA (steady-state mRNA). The result
obtained by agarose-gel electrophoresis experiment
of ampliﬁed cDNA from BrU-labeled mRNA shows a
smear pattern identical to or very similar to that of
ampliﬁed cDNA from non-labeled mRNA (data not
shown). This result suggests that both the reverse-
transcription efﬁciency and the ampliﬁcation efﬁ-
ciency were almost identical between BrU-labeled
RNA and non-labeled RNA. A self–self hybridization
experiment was conducted with ampliﬁed cDNA
labeled with Cy3/Cy5, and we detected gene
expression levels with broad signal ranges. The
ratios of Cy5 to Cy3 in all genes were in the range
of 0.5–2.0 (Fig. 4C), indicating that our DNA microar-
ray analysis is highly reproducible.
3.6. DNA microarray analysis of nascent RNA in mouse
G2 phase-arrested FT210 cells
We then compared the expression proﬁles of
nascent RNAs of 32 000 transcript products
between asynchronous mouse FM3A cells and G2
phase-synchronized FM3A cells. To obtain a highly
synchronized population of G2 phase cells, we chose
tsFT210 cells, which are temperature-sensitive Cdc2
mutant cells of mouse mammary carcinoma FM3A
cells.
14,15 tsFT210 cells are grown at 328C (the per-
missive temperature), but in the G2 phase, they are
arrested at 398C (Fig. 5A). With this cell line, a
highly synchronized population of cells is easily avail-
able by just shifting the culture temperature. It has
already been shown that such synchronization is
merely a result of the inactivation of just one
protein (CDC2 protein).
15 We also analyzed steady-
state RNA expression proﬁles of asynchronous cells
and G2-synchronized cells. Scatter plots of the
expression level are shown in Fig. 5B. Considering
the variation of DNA microarray data, we regarded
the genes that showed changes exceeding twofold as
either up- or down-regulated genes. Figure 5C shows
Venn diagram analyses of genes whose expression was
up- or down-regulated more than twofold in nascent
RNA and steady-state RNA. There was no gene whose
nascent RNA was up-regulated, whereas its steady-
state RNA was down-regulated, and vice versa.
Among the genes whose nascent RNA levels
changed more than twofold, cell cycle progression-
related genes are listed in Table 1. Of the 18 genes
listed, 14 genes exhibited fold changes in the analysis
of nascent RNA but not in that of steady-state RNA.
We found interesting expression proﬁles in Cdkn1a.
Cdkn1a (p21) was up-regulated in both analyses
(Table 1). Although this gene was previously reported
Figure 3. Binding speciﬁcity in immunoprecipitation with spike-in
controls. (A) Overview of the experiment. (B) Br-eGFP and
luciferase cRNA were prepared as spike-in controls. ‘Ratio
(eGFP/Luci.)’ represents the ratio of the eGFP cDNA copy
number to the luciferase copy number. Error bars represent
standard errors of the means (n ¼ 3).
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sition from the G1 phase to the S phase or from the G2
phase to the M phase,
17 the changes in the expression
proﬁles of the gene at the G2 phase were not ana-
lyzed. As up-regulation of the steady-state RNA and
nascent RNA of this gene is clearly observed, it
follows that this gene may have an important function
in the transition from the G2 phase to the M phase.
In addition to Cdkn1a, we have found that Pak1 and
Pak2 also exhibited interesting expression proﬁles. The
changes in expression levels of these genes were
detected in the analysis of only the nascent RNAs.
The PAK family is involved in microtubule and actin
cytoskeleton reorganization.
18 PAK1 and PAK2 inter-
act with centrosomal kinase Aurora-A, and activated
PAK1 phosphorylates Aurora-A in mitosis.
19 On the
other hand, the injection of 58 kDa active Pak1 into
Xenopus oocytes inhibits cell cleavage by arresting
G2/M progression,
20 suggesting that these products
have different role at these phases. These results of
DNA microarray analysis indicate that mRNAs of
these genes were not only synthesized but also
degraded between the G2 phase and the M phase.
As it is likely that synthesis and degradation occur in
Figure 4. (A) Eluted RNAs were converted to cDNA, and cDNA was ampliﬁed by TS-PCR. (B) Validation with quantitative RT–PCR of the
DNA microarray data using each ampliﬁcation method. Genes expressed at various levels in the non-ampliﬁcation method, TS-PCR
ampliﬁcation method, and T7 in vitro transcription (IVT) ampliﬁcation method were conﬁrmed using quantitative RT–PCR.
Quantitative RT–PCR was performed using the total RNA of these transcription factors. Gapd was used as the control. The same total
RNA was used for quantitative RT–PCR and DNA microarray experiments. The ratio of the total target RNA levels was normalized by
using those of the Tbp (Mus musculus TATA box binding protein) gene, and the fold change for each gene in the differentiated ES
cells compared to the control ES cells was calculated. Error bars represent standard deviations of log (base 2) of ratio. (C) Ampliﬁed
cDNA labeled with Cy3/Cy5 underwent self-self hybridization.
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changes in expression levels of these gene mRNAs
just by analyzing the steady-state levels.
We also found that Rplp2, Rpl27, Rps25, Rpl9, and
Rps29, which are categorized as ribosomal proteins,
were down-regulated at the G2 phase (Table 2).
Interestingly, the changes in the expression of these
genes were not detected in steady-state RNA,
although they were detected in the nascent RNA
analysis (Table 2). Changes in gene expression were
not detected in other ribosomal proteins in both ana-
lyses. Therefore, it is possible that these ﬁve ribosomal
proteins have distinct features in their gene expression
regulatory mechanisms. A previous study predicted
binding sites in transcriptional regulatory regions or
promoters of mammalian ribosomal protein genes
for transcriptional factors.
21 Those authors observed
that genes for these ﬁve ribosomal proteins lack
TATA-box and A/T-rich sequences similar to the TATA
box, whereas two-thirds of the genes for ribosomal
proteins have the TATA box or its homolog in their pro-
moter regions. Another study found that a unique
sequence (a tandem repeat of the TCTCGCGAGA
motif) does exist among many human genes that
lack the TATA box.
22 This sequence motif was found
at especially high frequencies in the genes for cell
cycle regulators as well as in human ribosomal
Figure 5. DNA microarray analyses of nascent RNAs. (A) FT210
cells were synchronized in the G2 phase by incubation at
39 8C for 17 h. Cell cycle proﬁles of asynchronous cells and
G2-arrested cells were analyzed by propidium iodide staining
and ﬂow cytometry. (B) Scatter plots comparing the expression
proﬁles of asynchronous cells with those of G2-arrested cells in
a nascent RNA proﬁle (left panel) and a steady-state RNA
proﬁle (right panel). (C) The Venn diagrams show the overlap
of genes whose expression levels changed more than twofold
in the nascent RNA proﬁle and the steady-state RNA proﬁle.
Table 1. The partial lists of cell cycle related genes whose level of
nascent RNAs changed more than twofold in G2 arrested cells
Gene
symbol
Fold changes
of nascent
RNA
Fold changes
of steady-
state RNA
Description
Cdkn1a 2.00 3.29 Cyclin-dependent kinase
inhibitor 1A (P21)
Pdgfa 2.41 3.02 Platelet derived growth
factor, alpha
Ppm1b 2.15 1.10 Protein phosphatase 1B,
magnesium dependent,
beta isoform
Bin1 2.53 1.41 Bridging integrator 1
Cdkl2 2.16 1.68 Cyclin-dependent kinase-
like 2 (CDC2-related
kinase)
Arhgef5 2.26 0.90 Rho guanine nucleotide
exchange factor (GEF) 5
Ppp1r15b 2.03 0.92 Protein phosphatase 1,
regulatory (inhibitor)
subunit 15b
Klf3 2.44 1.23 Kru ¨ppel-like factor 3
(basic)
Pak2 2.11 0.94 P21 (CDKN1A)-activated
kinase 2
Pdpk1 3.30 1.04 3-phosphoinositide
dependent protein
kinase-1
E2F5 2.13 0.83 E2F transcription factor 5
Pak1 2.09 1.47 P21 (CDKN1A)-activated
kinase 1
Gchfr 2.84 1.12 GTP cyclohydrolase I
feedback regulator
Tk1 0.41 0.46 Thymidine kinase 1
Ak1 0.40 0.48 Adenylate kinase 1
Dusp1 0.38 1.52 Dual speciﬁcity
phosphatase 1
Stk17b 0.38 0.60 Serine/threonine kinase
17b (apoptosis-inducing)
Pnrc2 0.29 0.89 Proline-rich nuclear
receptor co-activator 2
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upstream regions of three genes (Rpl9, Rps29, and
Rps25) out of the ﬁve genes that exhibit changes in
gene expression in only the nascent RNA analysis. As
translational control is also regarded as an important
mechanism for cell cycle regulation, it is possible to
obtain new insight into cell cycle regulation in the
G2 phase by performing functional analyses of these
ribosomal proteins.
3.7. Applications of comprehensive nascent RNA
expression analyses
These examples indicate that our DNA microarray
analysis of nascent RNAs has advantages over DNA
microarrayanalysisofsteady-statemRNAs.Oneadvan-
tage is that it can provide numerous insights into the
regulatory mechanism underlying gene expression.
For example, as the changes in expression levels of
many transcription factors are relatively small in
the process of cellular differentiation, our new
method will give us novel insights into the structure
of the gene expression regulatory network, since
this method can detect slight expression changes.
Collecting time-course data on nascent RNAs will also
provide important information.
Recently, Kenzelmann et al.
23 reported that nascent
RNAs could be analyzed by DNA microarray. In their
report, the nascent RNAs were mRNAs labeled using
4-thiol uridine and then puriﬁed using afﬁnity beads
whose surfaces were coated with a toxic organomer-
cury compound.
23 In our method, precipitation was
performed using Dynabeads, which are commonly
used in classical immunoprecipitation and do not
contain a heavy metal. This is another advantage of
our method. Although the DNA microarray used in
this study is an oligo-DNA microarray, this method is
applicable to other platforms such as cDNA micro-
array or Affymetrix’s GeneChip.
In summary, our study provides very useful tech-
niques for isolating nascent RNAs with high speciﬁcity.
By comparing the data between steady-state RNAs
and nascent RNAs, we can analyze changes in gene
expression with much higher sensitivity. We can also
determine the kinetics of transcription by combining
the DNA microarray study of nascent mRNAs with
that of existing mRNAs. The application of such an
analysis will provide important information in the
ﬁeld of transcriptome analysis. Microarray data of
transcripts whose nascent RNAs labels changed
more than twofold in G2 arrested cells are showed
in supplementary data.
Supplementary Data: Supplementary data are avail-
able online at www.dnaresearch.oxfordjournals.org.
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